HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis.
Anders Wilder EricksonFarinaz GhodratiSteven HabbousKatarzyna Joanna JerzakArjun SahgalManmeet S AhluwaliaSunit DasPublished in: Neuro-oncology advances (2020)
These findings support a potential role for systemic HER2-targeted therapy in the treatment of patients with IMD from HER2-positive metastatic breast cancer.